Who are PEG Asparaginase at six weeks interval's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Asparlas, ASPARAGINASE ERWINIA CHRYSANTHEMI, Elspar, L-asparaginase, recombinant asparaginase, Fe-ASP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peg-asparaginase-at-six-weeks-interval.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

PEG Asparaginase at six weeks interval — Competitive Intelligence Brief

PEG Asparaginase at six weeks interval (PEG Asparaginase at six weeks interval) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme (asparagine depleting agent). Area: Oncology.

phase 3 Enzyme (asparagine depleting agent) Asparagine Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PEG Asparaginase at six weeks interval (PEG Asparaginase at six weeks interval) — Rigshospitalet, Denmark. PEG Asparaginase depletes the amino acid asparagine in the bloodstream, starving leukemic cells that cannot synthesize their own asparagine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PEG Asparaginase at six weeks interval TARGET	PEG Asparaginase at six weeks interval	Rigshospitalet, Denmark	phase 3	Enzyme (asparagine depleting agent)	Asparagine
Asparlas	calaspargase	Pfizer	marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	2018-01-01
ASPARAGINASE ERWINIA CHRYSANTHEMI	ASPARAGINASE ERWINIA CHRYSANTHEMI		marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	2011-01-01
Elspar	ASPARAGINASE	Merck & Co.	marketed	Asparagine-specific Enzyme [EPC]	L-asparagine	1994-01-01
L-asparaginase	L-asparaginase	ERYtech Pharma	marketed	Enzyme (asparagine depleting agent)	Asparagine (substrate depletion mechanism)
recombinant asparaginase	recombinant asparaginase	medac GmbH	marketed	Enzyme	Asparagine
Fe-ASP	Fe-ASP	Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.	marketed	Asparaginase conjugate	Asparagine synthetase (indirect target via asparagine depletion)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme (asparagine depleting agent) class)

ERYtech Pharma · 1 drug in this class
First Affiliated Hospital of Zhejiang University · 1 drug in this class
Rigshospitalet, Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PEG Asparaginase at six weeks interval — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-asparaginase-at-six-weeks-interval. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab